Prospective non-invasive follow-up of liver fibrosis in patients with chronic hepatitis C

Journal of Gastrointestinal and Liver Diseases

Volumn 21, Issue 4, 2012, Pages 375-382

  Crisan, Dana ^a   Radu, Corina ^a,b   Grigorescu, Mircea Dan ^a,b   Lupsor, Monica ^a,b   Feier, Diana ^a   Grigorescu, Mircea ^a,b  

^a REGIONAL INSTITUTE OF GASTROENTEROLOGY AND HEPATOLOGY   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Chronic hepatitis C; Fibrosis; Follow up; Non invasive methods

Indexed keywords

ASPARTATE AMINOTRANSFERASE; HYALURONIC ACID; PEGINTERFERON; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE SURVEILLANCE; ECHOGRAPHY; ELASTOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PROSPECTIVE STUDY; RIGIDITY; SCORING SYSTEM; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BIOPSY; DISEASE PROGRESSION; ELASTICITY IMAGING TECHNIQUES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84875075289     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Camma C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004;39:333-342.
2. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fbrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-1313.
3. Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol 2009;50:1-3.
4. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68 276 biopsies. J Hepatol 1986;2:165-173.
5. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic Fatty liver disease. Gastroenterology 2005;128:1898-1906.
6. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-2618.
7. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both signifcant fbrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526.
8. Calès P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fbrosis. Hepatology 2005;42: 1373-1381.
9. Forns X, Ampurdanes S, Llovet JM, et al. Identifcation of chronic hepatitis C patients without hepatic fbrosis by a simple predictive model. Hepatology 2002;36:986-992.
10. Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of HALT-C cohort. Hepatology 2005;42:282-292.
11. Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fbrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997;92:1302-1304.
12. Imbert-Bismut F, Ratziu V, Pieroni L, et al; MULTIVIRC Group. Biochemical markers of liver fbrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-1075.
13. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fbrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350.
14. De Ledinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fbrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006;41:175-179.
15. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006;55:403-408.
16. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fbrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48-54.
17. Laharie D, Zerbib F, Adhoute X, et al. Diagnosis of liver fbrosis by transient elastography (FibroScan) and noninvasive methods in Crohn's disease patients treated with methotrexate. Aliment Pharmacol Ther 2006;23:1621-1628.
18. Corpechot C, El Naggar A, Poujol-Robert A, et al. Assessment of biliary fbrosis by transient elastography in patients with PBC and PSC. Hepatology 2006;43:1118-1124.
19. Lichtinghagen R, Bahr MJ. Noninvasive diagnosis of fbrosis in chronic liver disease. Expert Rev Mol Diagn 2004;4:715-726.
20. Sebastiani G, Alberti A. Non invasive fbrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006;12:3682-3694.
21. Zois CD, Baltayiannis GH, Karayiannis P, Tsianos EV. Systematic review: hepatic fbrosis-regression with therapy. Aliment Pharmacol Ther 2008;28:1175-1187.
22. Sandrin L, Fourquiet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fbrosis. Ultrasound Med Biol 2003;29:1705-1713.
23. Lupsor M, Badea R, Stefanescu H, et al. Analysis of histopathological changes that infuence liver stiffness in chronic hepatitis C. Results from a cohort of 324 patients. J Gastrointestin Liver Dis 2008;17:155-163.
24. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperation Study Group. Hepatology 1994;20:15-20.
25. Hézode C, Castéra L, Roudot-Thoraval F, et al. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther 2011;34:656-663.
26. Vergniol J, Foucher J, Mamou K, et al. Non-invasive evaluation of liver fbrosis using FibroScan in long-term sustained-virological responder patients after HCV treatment. Gastroenterol Clin Biol 2008;32:1061-1063.
27. Vergniol J, Foucher J, Castéra L, et al. Changes of non-invasive markers and FibroScan values during HCV treatment. J Viral Hepat 2009;16: 132-140.
28. Wang JH, Changchien CS, Hung CH, et al. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan. J Gastroenterol Hepatol 2010;25:964-969.
29. Patel K, Benhamou Y, Yoshida EM, et al. An independent and prospective comparison of two commercial fbrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa- 2b combination therapy for chronic hepatitis C. J Viral Hepat 2009;16:178-186.
30. Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008;47:380-384.
31. Sagir A, Erhardt A, Schmitt M, Haussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 2008;47:592-595.
32. Coco B, Oliveri F, Maina AM, et al. Transient elastography: a new surrogate marker of liver fbrosis infuenced by major changes of transaminases. J Viral Hepat 2007;14:360-369.
33. Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res 2009;83:127-134.
34. Ismail MH, Pinzani M. Reversal of liver fibrosis. Saudi J Gastroenterol 2009;15:72-79.
35. Everson GT, Balart L, Lee SS, et al. Histological benefits of virological response to peginterferon alpha-2a monotherapy in patients with hepatitis C and advanced fbrosis or compensated cirrhosis. Aliment Pharmacol Ther 2008;27:542-551.
36. Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010;51:2069-2076.
37. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008;149:399-403.
38. Furusyo N, Kajiwara E, Takahashi K, et al; Kyushu University Liver Disease Study (KULDS) Group. Association between the treatment length and cumulative dose of pegylated interferon alpha- 2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group. J Gastroenterol Hepatol 2008;23:1094-1104.